Attovia Therapeutics ($ATTO) Stock Hub 2026: ATTO-1310 Shows Preliminary Clinical Proof of Concept in Itch, Complete Phase 1b Data Expected in Q4 2026, Cash Funded Into 2030

01 Executive summary: a funded anti-IL-31 company with single-dose proof of concept and a fourth-quarter readout

Attovia Therapeutics is a San Carlos, California biotechnology company incorporated in December 2022 and operating since June 2023 around a licensed antibody platform, listed on August 5, 2026, and now valued by the market at roughly $1.06 billion on the September 2 close of $23.13 and 45,651,262 shares, a Merlintrader calculation. It has 44 employees, no approved product and $1.85 million of collaboration revenue in its history, $1.4 million in 2025 and $0.45 million in the second quarter of 2026, all from one platform licence. What it does have is a set of single-dose results in two itch indications that the company describes as clinical proof of concept, a cash position that management says lasts into 2030, and a register dominated by the venture funds that built it.

The molecule that carries the valuation is ATTO-1310, an Fc-fusion protein built from two camelid-derived binding domains, called an ATTOBODY, that binds the interleukin-31 cytokine directly rather than its receptor, with a half-life extended by the YTE mutation on its Fc portion. IL-31 is the cytokine most associated with itch, and the pathway is already validated by nemolizumab, approved in 2024 for prurigo nodularis and atopic dermatitis. Attovia’s argument, set out in the prospectus, is that binding the ligand instead of the receptor avoids the reverse dose-efficacy curve seen with nemolizumab, allows higher doses and deeper blockade, and supports dosing once every three months.

The evidence so far is a four-part Phase 1 trial. Parts 1 and 2, in 56 healthy volunteers, produced tolerability, pharmacokinetic and target engagement data: free IL-31 fell by more than 95% and stayed there for twelve weeks at doses of 4.5 mg/kg and above. Parts 3 and 4, in 26 patients with chronic pruritus and 26 with high-itch atopic dermatitis, produced the numbers that made the IPO: at week 4, 50% and 78% of treated chronic pruritus patients at the two doses reached a four-point reduction in peak itch against 0% on placebo, and lesion scores in the atopic dermatitis cohort improved by 61% and 51% against 17% on placebo. The complete data set is due in the fourth quarter of 2026.

The rest of the pipeline is preclinical. ATTO-2306 pairs the same IL-31 binders with an anti-IL-13 antibody derived from lebrikizumab, aimed at atopic dermatitis; ATTO-1091 is a trispecific against TL1A, IL-23 and integrin α4β7 for inflammatory bowel disease. Both are in IND-enabling work with Phase 1 starts planned for the first half of 2027, and the prospectus allocates $60 million to $80 million of the IPO money to taking ATTO-2306 through a Phase 2 in moderate-to-severe atopic dermatitis. The platform itself is licensed from Alamar Biosciences, which was paid in stock and holds about 7% of the company.

The reading is set out in full in the sections below. The short version is that the science is early but coherent, the funding question has been answered for several years, and the two things the market cannot yet know are whether the single-dose signal survives a placebo-controlled Phase 2 with proper statistics, and what the register looks like after January 31, 2027, when the lock-ups on roughly half the shares expire.

02 What Attovia is: a Frazier-built company on a platform licensed from Alamar

Attovia was incorporated in Delaware on December 16, 2022 and began principal operations in June 2023, formed by a group of investors including Frazier Life Sciences and Alamar Biosciences, to give the ATTOBODY platform, which Alamar had developed for its own diagnostic and research business, a dedicated therapeutics company. The founding chief executive, Tao Fu, is a Frazier venture partner; the chairman, James Topper, is a Frazier managing partner; the chief business officer, Zaneta Odrowaz, was Frazier’s vice president of company creation. The company is, in the plain sense, a Frazier company build, and the register reflects it.

An ATTOBODY is two heavy-chain-only antibody variable domains, the VHH or nanobody format naturally produced by camelids, joined by a proprietary peptide linker so that they bind two different epitopes on the same target, which the company calls biparatopic binding. The platform screens millions of VHH combinations in what the prospectus describes as an evolution-driven, high-throughput process. The properties the company claims for the format are high achievable affinity without affinity maturation, precise epitope selection, the ability to chain several ATTOBODIES into multispecific molecules without losing the activity of each arm, tunable half-life by fusion to Fc fragments or albumin-binding domains, and manufacturing with standard biologics processes. The prospectus states that more than 15 discovery campaigns have been completed with a 100% success rate in producing molecules that met the desired preclinical criteria, that a development candidate has been nominated within twelve months of starting discovery, and an IND submitted within two years.

The Alamar licence

The platform is not owned. It is licensed under an agreement originally signed on June 1, 2023 and amended and restated in October 2024 and April 2025. Alamar granted a worldwide, sublicensable licence to use the platform in the therapeutic field, exclusive with respect to Alamar’s patents and patent applications and non-exclusive with respect to its know-how. The consideration was 2,428,646 shares of common stock issued on June 1, 2023, a figure the prospectus states after the 1-for-9.29 reverse split, on top of the 800,632 shares Alamar received at the company’s formation in December 2022, plus up to $4.3 million per product in clinical and regulatory milestones and tiered royalties in the low single digits on net sales of each product. Attovia may terminate for convenience after a notice period; Alamar may terminate if Attovia challenges its patents. The prospectus lists the loss or termination of this licence among the risks that could harm the business, and it also discloses that Alamar was the company’s landlord in Fremont until March 2025 and a services provider. Alamar HoldCo held 3,229,279 shares, 7.5% of the post-offering count in the prospectus table, as of July 15, 2026.

The EndPath licence, and the only revenue

In July 2025 Attovia licensed part of the platform outward: EndPath RadioTherapeutics, formerly Isotovia Biosciences, received an exclusive worldwide licence to certain ATTOBODY technology for radioligand products, with Attovia performing initial research services on two targets. The agreement is accounted for as a customer contract; it produced $1.4 million of collaboration revenue in 2025 and $0.45 million in the quarter to June 30, 2026, the only revenue on the income statement. Milestones and royalties are possible under it, none disclosed as achieved.

03 IL-31, nemolizumab, and what ATTO-1310 is designed to do differently

Interleukin-31 is a cytokine produced mainly by T helper 2 cells that signals through a receptor made of IL-31 receptor alpha and the oncostatin M receptor, expressed on sensory neurons and keratinocytes among other cells. The prospectus describes it as the itch cytokine, elevated in atopic dermatitis, prurigo nodularis, cholestatic pruritus and chronic kidney disease-associated pruritus, and it reports the company’s own measurements: using a proprietary ultra-sensitive assay, serum IL-31 was low in every healthy volunteer sample and elevated in samples from patients with chronic pruritus of unknown origin and with atopic dermatitis obtained from two academic centres. That assay matters beyond the biology, because the company intends to use serum IL-31 as a biomarker for a pan-pruritic, precision-immunology development path across indications.

The clinical validation of the pathway belongs to nemolizumab, sold as Nemluvio, an antibody against the IL-31 receptor alpha approved by the FDA in 2024 for prurigo nodularis and atopic dermatitis. Attovia’s case for a second entrant is built on three stated limitations of that drug, all from the prospectus and therefore the company’s own framing: potency limited by a single epitope; a reverse dose-efficacy curve, in which higher doses performed worse than lower ones in adult atopic dermatitis, paediatric atopic dermatitis and CKD-associated pruritus, which capped the usable dose; and monthly dosing, with an option to extend to every two months after 16 weeks in atopic dermatitis only. The prospectus cites lokivetmab, an anti-IL-31 antibody used in dogs, as evidence that targeting the cytokine rather than the receptor gives a linear dose-response.

What ATTO-1310 is designed to do

ATTO-1310 binds the IL-31 ligand with a biparatopic ATTOBODY fused to an Fc fragment carrying the M252Y/S254T/T256E mutation, known as YTE, which increases binding to the neonatal Fc receptor and extends serum half-life. The four design goals listed in the prospectus are deep anti-pruritic responses, fast relief, a favourable tolerability profile and maintenance dosing as infrequent as once a quarter by subcutaneous injection. In cynomolgus monkeys challenged with IL-31, scratching fell for roughly 15 to 20 days after a single injection at 1 mg/kg and 5 mg/kg; in the GLP toxicology study the highest doses tested, 24 mg/kg intravenous and 8 mg/kg subcutaneous, were tolerated.

The indications named for the programme are chronic pruritus of unknown origin, high-itch mild-to-moderate atopic dermatitis, cholestatic pruritus in primary biliary cholangitis and primary sclerosing cholangitis, and chronic kidney disease-associated pruritus. The company’s commissioned market research, from LifeSci Consulting, an affiliate of one of the IPO underwriters, projects that by 2035 atopic dermatitis will affect 21 million adults and 10 million children in the United States, about a third with mild-to-moderate disease by EASI score, and that roughly 2 million adults and 1 million children in that band experience severe itch. In chronic pruritus of unknown origin there is no approved targeted therapy, and the prospectus notes that both nemolizumab and dupilumab are being developed there.

04 The Phase 1 trial: 56 volunteers, 52 patients, and twelve weeks of target engagement from one dose

The Phase 1 trial, NCT06787586 on ClinicalTrials.gov, is a randomised, double-blind, placebo-controlled study in four parts that started on January 14, 2025, with an enrolment of 108 across 17 sites in the United States and Canada and an estimated primary completion date listed as May 2026, a date that had passed without a registry update; the registry status was active, not recruiting, on September 3, 2026. Parts 1 and 2 enrolled 56 healthy volunteers, predominantly white, 59% female, with a mean age of 38.

In Part 1, 40 volunteers were randomised 3:1 to a single dose of ATTO-1310 or placebo, 32 intravenously at four ascending levels up to 9.0 mg/kg and 8 subcutaneously at 1.5 mg/kg. In Part 2, 16 volunteers received two subcutaneous doses at 1.5 mg/kg or 4.5 mg/kg on days 1 and 29. Treatment-emergent adverse events were reported by 26 subjects across both parts, mostly grade 1 or 2, with no increase in frequency with dose; the only grade 3 event was a vasovagal syncope during a blood draw in a placebo subject. Among 24 volunteers who received subcutaneous injections, 18 on drug, no injection site reactions were reported, and no treatment-related adverse events were identified at the highest intravenous dose. Of 42 subjects on active drug, two developed low-titre anti-drug antibodies, none neutralising or affecting exposure.

Pharmacokinetics were roughly dose-proportional with good subcutaneous bioavailability. The pharmacodynamic result is the one the dosing claim depends on: across all dose groups, the proportion of free IL-31 in serum fell by more than 95% rapidly and stayed there for twelve weeks at 4.5 mg/kg and above, with a dose-dependent pattern in depth and duration, in samples taken up to 112 days after dosing. In the patient cohorts of Parts 3 and 4 the same reduction of at least 95% from baseline was maintained for at least twelve weeks after a single dose.

Two features of Parts 3 and 4 shape how the efficacy numbers should be read. Rescue medication was prohibited for the first four weeks, and the company states that the four-week timepoint is the most relevant for assessing activity because patients received one dose; the sixteen-week data, still to come, will show what happens as exposure wanes. And efficacy was, by protocol, an exploratory objective: the study was designed to assess pharmacokinetics, tolerability, immunogenicity and pharmacodynamics, with clinical endpoints evaluated to demonstrate initial proof of activity.

05 The Phase 1b results in chronic pruritus and high-itch atopic dermatitis, number by number

The prospectus reports interim analyses from Parts 3 and 4 at week 4, presented by dose level and as pooled active arms, with the company noting that pooling was a choice made because of the small numbers. The endpoint is the peak pruritus numerical rating scale, PP-NRS, a daily patient-reported score from 0 to 10 for the worst itch in the past 24 hours, averaged weekly; a four-point reduction, PP-NRS 4, is the standard responder threshold in the field. Baseline scores were above 7 in every cohort, and mean age in the chronic pruritus cohorts was 60 to 62, consistent with the epidemiology of chronic pruritus of unknown origin.

In chronic pruritus the separation from placebo reached nominal statistical significance from week 3 for the 9.0 mg/kg cohort and from week 2 for the pooled arm; the EASI difference in atopic dermatitis is marked at p ≤ 0.01 in the prospectus figure. On responder definitions of increasing stringency, from EASI-50 through EASI-100 and IGA 0/1, the company reports that separation from placebo becomes more apparent, with no placebo patient achieving better than EASI-50. The prospectus also notes that, by chance, placebo patients in the atopic dermatitis cohorts started with higher EASI scores than the active arms, which is the kind of imbalance that small cohorts produce and larger ones dilute.

The comparisons the company draws, and their limits

The prospectus sets the numbers against published third-party data: in a Phase 3 of dupilumab in chronic pruritus of unknown origin, NCT05263206, about 18% of treated patients reached PP-NRS 4 at week 4; in atopic dermatitis subgroups with baseline PP-NRS of 7 or more, 19%, 32% and 28% of patients on dupilumab, lebrikizumab and nemolizumab reached PP-NRS 4 by week 4. Those are cross-trial comparisons between a 26-patient single-dose Phase 1b and registrational programmes with hundreds of patients, different populations, different background therapy and different statistical plans; they indicate the direction the company hopes to prove, not a proven advantage.

The company is explicit about the same limits in its risk factors. The Form 10-Q states that the Phase 1b looked at a number of exploratory efficacy measures, including by pooling results from different dose groups and without accounting for multiplicity, and that positive results, including statistically significant ones, may not be replicated in future trials with different designs and greater numbers of patients. The atopic dermatitis PP-NRS 4 rate is itself a caution: 63% at the lower dose and 30% at the higher, with a 25% placebo rate, is the pattern of a small sample rather than of a dose-response.

Tolerability in patients is reported as favourable, with most events grade 1 or 2 and no treatment-related serious or severe adverse events across volunteers and patients. Treatment-induced anti-drug antibodies appeared in one of 17 chronic pruritus patients and one of 13 atopic dermatitis patients with data available, none neutralising and none affecting exposure. The complete Phase 1b data expected in the fourth quarter of 2026 should add the sixteen-week timepoint, the full adverse event tables, secondary scales such as SD-NRS and SCORAD, and unblinded individual-level data.

06 The Phase 2 plan, the FDA protocol feedback and the China IND

The next stage is a Phase 2 programme that the company has been designing with the FDA’s input. On September 2, 2026 it said the protocol for the global Phase 2 study in chronic pruritus of unknown origin had been submitted to the agency after incorporating its feedback on key design elements and endpoints, with initiation planned for the first half of 2027. The prospectus describes the study as a Phase 2b intended to enable Phase 3: two dose levels at induction, given subcutaneously at weeks 0, 4 and 8, followed by a single dose level administered every 4 or every 12 weeks; a primary endpoint of itch improvement; secondary endpoints of itch, sleep and health-related quality of life plus safety; and exploratory measures that include safety, pharmacokinetics, pharmacodynamics and immunogenicity. The 12-week maintenance arm is where the quarterly dosing claim gets tested against the monthly one.

A second global Phase 2 in high-itch atopic dermatitis is planned for the same window. The prospectus budgets $110 million to $130 million of the IPO proceeds to take ATTO-1310 through both Phase 2 studies, which is the single largest line in the use of proceeds and the reason the runway estimate is measured in years rather than quarters.

Cholestatic pruritus, and the China route

The third clinical setting is non-inflammatory itch. A Phase 1b in patients with primary biliary cholangitis or primary sclerosing cholangitis is planned as a double-blind, placebo-controlled multiple ascending dose study with pharmacokinetics as the primary objective and itch scores as exploratory measures; the prospectus expected the first subject to be dosed in the second half of 2026. On September 2 the company said the IND for this trial had been cleared in China in under 30 working days through the National Medical Products Administration’s new expedited review pathway. The Shanghai subsidiary incorporated in October 2025 fits that plan, and the Form 10-Q also discloses that some contract manufacturing is done by third parties in China, with the policy and supply risks that implies. A second Phase 1b in chronic kidney disease-associated pruritus may follow.

The longer-term regulatory idea in the prospectus is a pan-pruritic path for patients with elevated IL-31, using the company’s serum assay to select or stratify patients across diseases. That is a strategy, not a filing: the FDA interactions disclosed so far concern the Phase 2 protocol in one indication. No breakthrough, fast track or orphan designation has been announced.

07 ATTO-2306, ATTO-1091 and the earlier pipeline

ATTO-2306 is the second immuno-dermatology candidate: two IL-31 ATTOBODIES, the same VHHs used in ATTO-1310, attached to an anti-IL-13 IgG derived from lebrikizumab and carrying the YTE half-life mutation. IL-13 and IL-31 are, in the company’s description, the only two clinically and commercially validated pathways in atopic dermatitis, and the bispecific is meant to control both lesions and itch while avoiding the target-mediated drug disposition seen with IL-4Rα antibodies and the reverse dose-efficacy seen with the IL-31 receptor antibody. It replaces an earlier candidate, ATTO-3712, mainly by extending the projected human half-life. Preclinical results reported in the prospectus are high potency for each arm whether tested alone or in the bispecific, a low projected immunogenicity risk and a long half-life, plus a high-concentration subcutaneous formulation. IND-enabling studies are ongoing, Phase 1 is planned for the first half of 2027, and the prospectus earmarks $60 million to $80 million to reach a Phase 2 in moderate-to-severe atopic dermatitis. Chronic spontaneous urticaria and prurigo nodularis are named as follow-on settings.

ATTO-1091 takes the platform into gastroenterology: a trispecific Fc fusion that blocks TL1A, IL-23p19 and integrin α4β7, three pathways each validated separately in inflammatory bowel disease by third-party trials, with binding optimised for all three arms. A dose-range-finding study in non-human primates produced no clinical safety observations and no histopathology findings; GMP process development and GLP toxicology are ongoing, and a randomised, placebo-controlled Phase 1 is planned for the first half of 2027, subject to IND clearance. The prospectus cites U.S. prevalence of about 1.1 million for ulcerative colitis and 1.0 million for Crohn’s disease.

Behind those three sits ATTO-006, a conditional AND-gated bispecific designed to block the survival of tissue-resident memory T cells only when both arms engage their targets, which the company is advancing toward development candidate nomination by the end of 2026, and a discovery effort on tetraspecific formats and novel targets. None of it has a disclosed budget beyond the residual line in the use of proceeds.

08 The IPO: from 12.5 million shares at $15 to $17 to 19.55 million at $17.00, and who bought

The path to the listing is documented filing by filing. A confidential draft registration statement was submitted on December 19, 2025, amended in February and June 2026, and the public Form S-1 was filed on July 14, 2026. On July 22 the board approved a reverse stock split of 1-for-9.29, effected on July 29, so that every share and per-share figure in the financial statements is restated on that basis. The S-1/A of July 29 marketed 12,500,000 shares at $15.00 to $17.00, with an option on 1,875,000 more. On August 4 the registration statement was declared effective and the offering priced at the top of the range and larger: 17,000,000 shares at $17.00, $289.0 million gross, with an option on 2,550,000 shares. Trading began on August 5 on the Nasdaq Global Market; the first Marketstack close was $21.90 that day. The offering closed on August 6 with the option exercised in full: 19,550,000 shares, $332.4 million gross, approximately $305.4 million net. Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets were joint book-runners, with LifeSci Capital as passive book-runner.

At the closing, every share of redeemable convertible preferred stock, carried at $258.2 million on the June 30 balance sheet, converted into 21,517,976 common shares, and the certificate of incorporation was amended to authorise 500,000,000 common and 10,000,000 preferred shares. The prospectus table counted 43,097,458 shares after the offering before the option; the Form 10-Q cover reports 45,651,262 shares outstanding at August 31, 2026, the number every percentage on this coverage uses. At the $17.00 offer price that count is worth about $776 million, a Merlintrader calculation; at the September 2 close of $23.13 it is about $1.06 billion.

Who bought at $17.00

The ownership filings made in the two weeks after the closing are unusually informative for a new listing, because several existing holders bought in the offering and said so. The Frazier Schedule 13D of August 11 itemises purchases by three funds: 617,758 shares by Frazier Life Sciences Public Fund, 588,235 by Frazier Life Sciences XI and 44,007 by Frazier Life Sciences XII, all from the underwriters at $17.00 for a combined $21,250,000; then open-market purchases on August 5 of 100,000 shares at $21.77 to $22.00 for $2,190,790, on August 6 of 50,000 shares at $20.36 to $21.88 for $1,061,850, and on August 7 of 2,725 shares at $19.37 to $20.00 for $53,728.83. The group holds 6,968,703 shares. Goldman Sachs entities, through vehicles managed by Goldman Sachs Asset Management and Broad Street Principal Investments, bought 500,000 shares in the IPO and hold 3,020,632, per the Form 4/A of August 28; the same filing reports market-making trades by Goldman Sachs & Co. on August 5, 85,000 shares bought and 105,807 sold, which are dealer activity and not an investment decision. venBio bought 382,352 shares in the offering and holds 4,181,367; Redmile Group bought 600,000 and holds 1,182,854; Sanofi, which held preferred stock from the private rounds, bought 300,000 and holds 1,082,855.

These are fixed-price allocations in a registered offering and open-market purchases reported by the holders, not insider buying in the sense of officers spending their own money: no officer or director has reported an open-market purchase. But a syndicate in which the largest existing holders took about $51.5 million of a $332 million deal, and one of them kept buying at $20 to $22 in the first three sessions, is a fact about the register that the prospectus alone did not show.

09 The quarter to June 30, 2026 and the balance sheet before the money arrived

The quarter to June 30, 2026 is the last one before the IPO money, so it shows the business at its private-company run-rate. Collaboration revenue was $450,000, from services under the EndPath agreement, against nothing a year earlier. Research and development expense was $18.9 million, up from $13.6 million, driven by clinical, manufacturing and preclinical costs to finish the ATTO-1310 Phase 1 and by manufacturing and preclinical costs for ATTO-2306 and ATTO-1091. General and administrative expense was $3.3 million, up from $3.0 million on personnel and public-company readiness. The operating loss was $21.8 million, interest income $1.1 million, and the net loss $20.7 million, or $4.88 per share on 4,237,597 weighted average shares, a denominator that predates the preferred conversion and is therefore not comparable with the post-IPO count.

For the six months, revenue was $0.45 million, R&D $35.7 million against $25.4 million, G&A $6.5 million against $7.3 million, and the net loss $39.3 million against $29.6 million. The XBRL data give the first quarter of 2026 directly at $18.7 million of net loss, so the second quarter was the larger of the two. Full-year net losses were $60.6 million in 2025 and $39.8 million in 2024.

The two net loss lines differ only in the first half of 2025, where $271,000 of accretion on the preferred stock is deducted to reach the amount attributable to common stockholders; in 2026 the figures coincide. Interest income has fallen from $2.0 million to $1.1 million a quarter as the private-round cash was spent, and will rise again once the IPO proceeds are invested.

The balance sheet at June 30, and what changed on August 6

Cash, cash equivalents and marketable securities were $115.1 million at June 30, 2026, split between $32.8 million of cash and $82.3 million of marketable securities, down from $152.3 million at December 31, 2025. Total assets were $128.3 million and total liabilities $15.6 million, with no debt disclosed. Below the liabilities sat $258.2 million of redeemable convertible preferred stock and a stockholders’ deficit of $145.5 million, which is the accounting shape of a venture-backed company before its preferred converts; the accumulated deficit was $150.4 million. Operating activities used $34.9 million in the six months, against $26.7 million a year earlier, and investing activities provided $29.4 million as securities matured. Financing activities used $1.8 million in the half, mainly payments of deferred offering costs, against $142.0 million provided in the first half of 2025 by the Series B second tranche and the Series C.

None of the June 30 figures reflect the IPO, which closed after the period end. Adding the approximately $305.4 million of net proceeds to the $115.1 million balance gives about $420.5 million, a Merlintrader calculation that ignores whatever was spent in July and August and the offering costs already capitalised, $2.5 million of which sat in non-current assets at June 30 and was charged against the proceeds at closing. The next balance sheet with the money on it is the third quarter Form 10-Q.

10 Cash, use of proceeds and the two runway statements

Two runway statements exist, and they differ by a year. The prospectus of August 5, written when the base deal was 17,000,000 shares and net proceeds were estimated at $265.1 million, or $305.4 million with the option, said existing cash plus the offering would fund operations into 2029. The Form 10-Q and the September 2 release, written after the option was exercised in full, say into 2030. The company has not published a burn forecast, so the extension cannot be reconciled from the outside beyond the extra $40.3 million of net proceeds; both are management estimates that the filings say may prove wrong.

The arithmetic that can be done is simple. Operating cash used was $34.9 million in the first half of 2026, about $5.8 million a month, and $60.6 million of net loss for all of 2025. Against about $420.5 million of pro forma cash, that rate would last roughly six years, which is longer than the company itself claims, and the difference is the spending plan: the prospectus says expenses will increase substantially as ATTO-1310 enters two Phase 2 studies, ATTO-2306 and ATTO-1091 enter the clinic and headcount grows in clinical operations, manufacturing, regulatory affairs and finance. Into 2030 therefore implies an average burn well above the current one, in the region of $100 million a year on a Merlintrader reading, which is what two global Phase 2 programmes and two Phase 1 programmes cost.

The prospectus is equally clear about what the money does not cover: the proceeds together with existing cash will not be sufficient to fund ATTO-1310, ATTO-2306, ATTO-1091 or any other candidate through regulatory approval, and substantial additional capital will be needed. It also lists a use it has no plans for but reserves, in-licensing or acquisitions, with no negotiations under way. There is no debt, no at-the-market programme and no shelf registration on file as of September 3, 2026; as an emerging growth company with a first Form 10-K due for 2026, Attovia cannot in any case use a short-form shelf until it has been reporting for twelve months.

The Alamar milestones, up to $4.3 million per product, and the EndPath economics are the only contractual cash items disclosed, and neither is large at this stage. Lease obligations for the San Carlos site are the main fixed commitment. The Form 10-Q’s going-concern language is the standard one for a funded company: existing resources plus the IPO proceeds are sufficient for at least twelve months from the issuance of the statements.

11 Share structure, equity plans and the January 31, 2027 lock-up

The share count has three layers. The base is 45,651,262 shares outstanding at August 31, 2026, made of the 4,529,100 common shares at June 30, the 21,517,976 shares from the preferred conversion, the 19,550,000 IPO shares and a remainder of 54,186 shares issued between June 30 and August 31 that the Form 10-Q does not itemise, after the 1-for-9.29 reverse split of July 29 that also multiplied the per-share numbers in every earlier document. Above it sits the equity compensation layer: the 2026 Equity Incentive Plan became effective on August 3 with 4,900,000 shares reserved plus whatever was unused under the 2023 Plan, and the board approved option grants covering 1,642,700 shares at the $17.00 IPO price to employees, consultants and directors upon effectiveness of the registration statement, subject to service-based vesting. The 2026 Employee Stock Purchase Plan, effective August 4, reserves 410,000 shares and increases automatically by up to 1% of outstanding shares each January 1 from 2027 through 2036.

The third layer is timing. Officers, directors and substantially all pre-IPO stockholders signed lock-up agreements that expire on January 31, 2027, and the Form 10-Q names Morgan Stanley, Leerink, Citigroup and RBC as able to release any of them earlier at their sole discretion. On the Merlintrader calculation in the register chart above, about 47% of the shares belong to seven disclosed holders, and a further, unquantified share to management, employees and smaller pre-IPO holders; all of that is locked until then. The prospectus risk factor puts it plainly: sales of a substantial number of shares, or the perception that holders intend to sell, could cause the price to decline significantly.

Dilution in the ordinary sense, new issuance for cash, is not on the near-term calendar: the IPO answered the funding question for a period the company measures in years. The dilution that exists is the compensation layer, which is a few per cent a year at the reserve sizes disclosed, and the potential supply from the lock-up expiry, which is a change in who holds the shares rather than in how many there are. The prospectus also warns that the IPO itself may have triggered an ownership change under Section 382 of the tax code, limiting the use of net operating losses; with $150.4 million of accumulated deficit and no taxable income in sight, that is a long-dated point.

12 Who owns $ATTO: the register after the IPO filings

The register is the most fully documented part of a company that is four weeks old on the market, because the Section 16 and Schedule 13 filings came in a cluster between August 6 and 28. The table combines them. Percentages are Merlintrader calculations on the August 31 share count; each holding carries the date of its own filing, and holdings dated July 15 come from the prospectus table and may have changed.

Three observations follow. First, the disclosed IPO purchases by existing holders total 3,032,352 shares, or $51.55 million at $17.00, about 15.5% of the 19,550,000 shares sold, a Merlintrader sum of the figures in the filings. Second, Sanofi is on the list: a strategic holder from the private rounds that added in the IPO, without any collaboration disclosed between the two companies, and the maker of dupilumab, the drug the company benchmarks against in chronic pruritus. Third, the only open-market buying reported is Frazier’s 152,725 shares on August 5-7 at $19.37 to $22.00; Goldman’s August 5 trades were market-making by the broker-dealer, and no officer or director has filed a purchase. A Form 144 was filed on August 28, which is a notice of a proposed sale and not a sale, and is left out of the count.

The board reflects the register. James Topper of Frazier chairs it; Mitchell Gold is a Frazier venture partner; Colin Walsh is a managing director in Goldman Sachs’ life sciences investing group and reports the Goldman entities’ holdings on his own Form 4/A of August 28, 2026, disclaiming beneficial ownership; Aaron Royston and Angie You complete the investor and industry directors, and John W. Smither, appointed on July 15, 2026 as independent director and audit committee chair, is chief financial officer of MBX Biosciences and a senior adviser to Frazier Life Sciences. The same July 15 release announced that Yuling Luo, co-founder, director and inventor of the ATTOBODY technology at Alamar, would step down from the board; the company said the partnership with Alamar continues through its biomarker assay technology. The prospectus discloses related-party dealings with Alamar, the licensor and former landlord, and states that no IPO expenses were paid to officers, directors or 10% holders.

13 Management, board and governance

The executive team is small and its record is in business development and clinical operations at larger companies rather than in taking a first product through approval as a founder. Tao Fu, founder, chief executive and president since April 2023, was president and chief operating officer of Zai Lab from 2018 to 2022, chief commercial and business officer of Portola Pharmaceuticals from 2015 to 2018, led M&A and corporate development at Bristol Myers Squibb and spent eleven years at Johnson & Johnson, latterly as vice president and head of pharmaceutical M&A. He remains a venture partner at Frazier Life Sciences and a director of Tr1X. Zaneta Odrowaz, co-founder and chief business officer, came from Frazier’s company creation group and, before that, corporate development at Amunix, acquired by Sanofi. Petter Veiby, co-founder and chief scientific officer, spent two decades at Takeda Oncology and Millennium to 2020, latterly as global head of biotherapeutics, then held business development roles at Zai Lab and Immunitas and returned to Takeda Oncology as senior director before joining in June 2023. Hubert Chen, chief medical officer since March 2024, was senior vice president of clinical development at Krystal Biotech from October 2021 to March 2024 and spent ten years at Genentech, latterly as principal medical director. Steven Chan, chief financial officer since October 2024, was CFO of Connect Biopharma and held finance roles at Arcus and MyoKardia.

The governance points that a new holder should have in view are ordinary for a venture-built company and disclosed in the prospectus: a board led by the largest holder’s managing partner; a chief executive who is also a venture partner at that holder; a platform licensed from a shareholder that was also a landlord and service provider; and market research commissioned from an affiliate of an underwriter. Attovia is an emerging growth company, which allows reduced disclosure and an extended transition for new accounting standards, and its first Form 10-K, for 2026, will be the first with a full year of public-company reporting. No material weakness in internal controls is disclosed in the Form 10-Q.

Execution to date can be measured against the company’s own stated timelines. The Phase 1 started in January 2025 and completed dosing in the first quarter of 2026; the Phase 2 protocol went to the FDA with the agency’s feedback incorporated; the China IND was cleared; the IPO was completed above the marketed range; and John Smither’s appointment preceded the listing. The open items are the ones the company has scheduled: complete data in the fourth quarter, first patient in the cholestatic pruritus study, and three trial starts in the first half of 2027.

14 Competition: nemolizumab, dupilumab and the itch market

The competitive map for an IL-31 drug has one approved product and two large incumbents in the surrounding indications. Nemolizumab, Galderma’s Nemluvio, is the only marketed IL-31 pathway therapy, approved in 2024 for prurigo nodularis and atopic dermatitis, dosed monthly with an every-two-months option in atopic dermatitis after 16 weeks; the prospectus says it is also being developed in chronic pruritus of unknown origin. Dupilumab, Sanofi and Regeneron’s Dupixent, blocks IL-4Rα and is the largest atopic dermatitis product, $17.8 billion of 2025 sales on the prospectus’s figure out of nearly $21 billion for the whole category; it has a completed Phase 3 in chronic pruritus of unknown origin, NCT05263206, from which the company quotes an 18% PP-NRS 4 rate at week 4. Lebrikizumab, Lilly’s Ebglyss, is the IL-13 antibody from which ATTO-2306’s IL-13 arm is derived. In chronic kidney disease-associated pruritus the approved drug is intravenous difelikefalin, Korsuva, a kappa opioid agonist restricted to haemodialysis patients.

Attovia’s positioning is by indication and by dosing interval. In chronic pruritus of unknown origin there is no approved targeted treatment and the company’s comparison is against the dupilumab Phase 3 rate. In high-itch mild-to-moderate atopic dermatitis the company argues that no competitor has an active programme in that specific population, and that the relevant comparators are topicals with once- or twice-daily application, citing an approved topical with a placebo-adjusted PP-NRS 4 rate of about 37% at eight weeks. In moderate-to-severe atopic dermatitis, the setting for ATTO-2306, the comparators are the injectable biologics themselves, and the differentiation claimed is the combination of lesion and itch control from two pathways with a longer dosing interval.

What the prospectus does not provide is a head-to-head trial or a plan for one, and the cross-trial comparisons in it are between a single-dose Phase 1b and registrational programmes. The advantages that can be asserted on the September 3, 2026 record are mechanistic: ligand rather than receptor binding, a linear dose-response in animals, and target engagement that lasts twelve weeks after one dose. Whether those translate into a clinical difference against monthly nemolizumab or fortnightly dupilumab is the question the Phase 2 programme is designed to answer from 2027.

15 Analysts and targets

No analyst note on Attovia can be cited with the house and the exact date, and the table is therefore not shown. The syndicate banks, Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets and LifeSci Capital, would ordinarily be expected to initiate coverage after the quiet period that follows an IPO, but no initiation has been verified on a primary or first-tier source as of September 3, 2026, and the vendor consensus fields that aggregate such notes are not reproduced here without a source behind each entry. If and when initiations appear, they will be added with the date of each.

The only forward-looking financial statements available are therefore the company’s own: cash into 2030, expenses increasing substantially, no product revenue for years, and the use-of-proceeds allocations in the prospectus.

16 Retail sentiment on Stocktwits

The retail audience for a four-week-old symbol is, predictably, thin. The Stocktwits reading on September 3, 2026 shows a canonical sentiment score of 55 out of 100, labelled bullish by the platform, a message volume score of 53 labelled normal, 19 watchers, and no sentiment-tagged messages at all, which is why the usual bullish-versus-bearish split cannot be reported. The messages that exist are a handful: a post tallying the disclosed IPO purchases by Frazier, Goldman, Redmile, venBio and Sanofi, a fund manager noting that the August biotech IPO cohort had traded well in its first weeks while calling the company too early-stage for his own book, and syndicated IPO-market recaps. There is no thesis being argued, no price target being circulated and no dispute about the data, because almost nobody is there yet.

Reddit and X were not sampled for this reading, and no thread on either platform is cited; Stocktwits is the only retail source read, on September 3, 2026. These are opinions of retail traders and non-professional investors rather than analyst research; a sentiment reading on an audience of nineteen is a description of that audience and nothing more, and it has no bearing on what the complete Phase 1b data will show.

17 The catalyst map

Every catalyst below is the company’s own statement, with its date or window as given. None is a regulatory decision: Attovia has no application under review anywhere, and the next binary event of that kind is years away. The events that can move the shares in the next twelve months are data releases and trial starts, and the one dated item is a calendar event rather than a company decision.

Two things are absent from the list because the company has not stated them: a date for the ATTO-1310 data presentation, which could be a release, a medical meeting or both, and any timing for Phase 2 readouts, which on the design described, three induction doses and a maintenance period, would fall in 2028 at the earliest. The dates are registered in the Merlintrader Biotech Catalyst Calendar as company windows, marked as estimated where no day is given.

18 Risks and red flags

The data are small, single-dose and exploratory. The company’s own risk factor is the best summary: the Phase 1b looked at a number of exploratory efficacy measures, including by pooling results from different dose groups and without accounting for multiplicity, and positive results may not be replicated in larger trials with different designs. Four placebo patients per cohort is the arithmetic behind a 0% placebo response in chronic pruritus. The atopic dermatitis PP-NRS 4 rates, 63% at the lower dose and 30% at the higher, with 25% on placebo, show how much noise the numbers carry. The complete data could look better than the interim, or worse, and the sixteen-week timepoint after one dose is not the maintenance regimen of the Phase 2.

The proof of concept is against placebo, not against nemolizumab. Every efficacy claim on differentiation is a cross-trial comparison drawn by the company. An approved competitor with the same target pathway, a second one with Phase 3 results in the lead indication, and the largest dermatology franchise in the industry owned by a company that is also on Attovia’s register set a high bar for what a Phase 2 must show.

Concentration and the lock-up. About 47% of the shares are in seven disclosed holders on a Merlintrader calculation, the board is led by the largest holder, and the lock-ups on substantially all pre-IPO shares expire on January 31, 2027 or earlier at the book-runners’ discretion. Nineteen Stocktwits watchers and a symbol four weeks old describe a float that is thin until then.

Platform dependence on a licensor. Every candidate is built on technology licensed from Alamar, exclusive for patents but not for know-how, with termination rights if Attovia challenges Alamar’s patents. The prospectus lists the loss of that licence among the risks that could harm the business, and the patent estate itself is described as licensed rather than owned.

Spending will rise into an unproven programme. Into 2030 assumes a burn far above the current $5.8 million a month, and the money is committed by plan to two Phase 2 studies of ATTO-1310 and a Phase 2 of ATTO-2306 before any of those studies has read out. If the complete Phase 1b data disappoint, the plan and the runway would be revisited together.

China exposure. Part of contract manufacturing is done by third parties in China, a subsidiary was incorporated in Shanghai in October 2025, and the first cholestatic pruritus trial was cleared by the NMPA. The Form 10-Q lists supply disruption, cost increases and policy changes in either government as risks of that arrangement.

Ordinary early-stage biology. Anti-drug antibodies were seen at low rates and were non-neutralising; a longer-acting biologic that stays in circulation for months has, by design, a long tail if an adverse effect emerges. Immunogenicity, injection site reactions and the safety of chronic IL-31 blockade at doses higher than nemolizumab’s are questions for the multiple-dose Phase 2, not settled by 26 patients.

19 The constructive case in full

The constructive reading starts from the mechanism and the money. IL-31 is a validated itch target with an approved drug whose limitations are documented in its own label: monthly dosing and a dose ceiling set by a reverse dose-response. A ligand-binding, half-life extended molecule that suppresses free IL-31 by more than 95% for twelve weeks after one subcutaneous injection, in volunteers and in patients, is exactly the profile that would address those limitations, and the pharmacology is the part of the story that is measured rather than estimated.

The efficacy signal, for all its limits, points the right way at both doses and in both indications. In chronic pruritus of unknown origin, where nothing targeted is approved, 78% PP-NRS 4 at week 4 on the higher dose against 0% on placebo, and 44% itch-free or nearly so, are numbers that no incumbent has reported in that population, on the company’s comparison with the dupilumab Phase 3. In high-itch atopic dermatitis a monotherapy improved lesion scores by 51% to 61% at four weeks after one dose, which is the observation that makes ATTO-2306, the bispecific with IL-13 added, worth its $60 million to $80 million budget. Tolerability across 56 volunteers and 52 patients was unremarkable, with low, non-neutralising immunogenicity.

The financing removed the question that dominates most companies at this stage. An offering marketed at 12.5 million shares was sold at 19.55 million at the top of the range, the largest existing holders took about $51.5 million of it and one of them kept buying in the market, and the company says the balance sheet reaches 2030. That is enough to run both Phase 2 studies of ATTO-1310, the first Phase 2 of ATTO-2306 and the first Phase 1 of ATTO-1091 without returning to the market on the science’s timetable rather than the treasury’s. The platform has produced three candidates in two years and a licence to a radiopharmaceutical company, and the team has done approvals, launches and transactions at Genentech, Krystal, Portola, Zai Lab and Takeda.

On this reading, the fourth-quarter data are the near-term test, the 2027 trial starts are the execution test, and the multiple-dose Phase 2 results from 2028 are where a differentiated IL-31 franchise in three itch indications, plus a bispecific for the largest dermatology market, would either take shape or not.

20 The sceptical case in full

The sceptical reading starts from the sample size. Twenty-six patients per indication, randomised two to one, means the entire placebo comparison in chronic pruritus rests on about eight people across two cohorts and the 0% placebo response is a small-number artefact as much as a finding. The company chose to pool dose groups, did not correct for multiplicity, measured efficacy as an exploratory objective and reports a four-week timepoint after a single injection. Those are the standard conditions under which early biotech data look their best, and the Form 10-Q says so in its own words.

The competitive position is harder than the prospectus framing suggests. Nemolizumab is approved, marketed by Galderma and moving into chronic pruritus of unknown origin; dupilumab has completed Phase 3 there and its makers, Sanofi and Regeneron, have the resources to run any trial they choose, and Sanofi holds Attovia stock, which is information about Sanofi’s interest, not about Attovia’s prospects. ATTO-1310’s claimed advantages, quarterly dosing and deeper blockade, are inferences from pharmacokinetics and animal dose-response, to be proved in a Phase 2 that starts in 2027 and reads out no earlier than 2028. Until then the company has a $1.06 billion market value, on the September 2 close, resting on 52 patients.

The register and the calendar add a mechanical risk. Seven disclosed holders own about 47% of the shares, all locked until January 31, 2027 unless released earlier; the Frazier funds that hold 15% have been investors since the Series A-1 at a cost basis the 13D puts at roughly $60 million for 5.57 million converted shares, or under $11 a share, before their IPO and open-market additions. A venture fund does not hold for ever, and the first date on which it can sell is known. Meanwhile the operating loss is $20.7 million a quarter and rising, with no product revenue and a licence-based platform.

On this reading the fourth-quarter data are more likely to confirm the interim than to overturn it, because they come from the same 52 patients, and the questions that matter, dose-response over multiple doses, durability at twelve-week intervals, safety of sustained blockade and performance against active comparators, cannot be answered before 2028. The stock will trade on sentiment about those questions, and on supply, for the intervening eighteen months.

21 Scenarios

The scenarios below are descriptive and carry no probabilities or price levels; they are the branches that the company’s own calendar creates.

22 Bottom line

Attovia has done the two things a newly listed biotechnology company can be asked to do in its first month: it has put the money on the balance sheet, $332.4 million gross at a price above the marketed range with its own investors buying alongside, and it has shown data that separate from placebo in the endpoint that its lead drug is designed to move. The single-dose Phase 1b in chronic pruritus and high-itch atopic dermatitis, 26 patients each, produced 78% and 50% four-point itch responders at the two doses in chronic pruritus against 0% on placebo, and 51% to 61% lesion improvement in atopic dermatitis against 17%, on the back of a pharmacology, more than 95% suppression of free IL-31 for twelve weeks, that is the strongest part of the case.

What it has not done, and cannot do before 2028, is prove that ATTO-1310 is better than the approved IL-31 pathway drug or than dupilumab in the indications where those are being developed. The company says in its filings that the interim results are exploratory, pooled, uncorrected for multiplicity and may not replicate; the placebo arms are four patients per cohort; and the comparisons to competitors are across trials. The complete Phase 1b data in the fourth quarter of 2026 will add the sixteen-week timepoint and the full tables, but they come from the same 52 patients.

The financial picture is unusually clear for the sector. The June 30 balance sheet held $115.1 million; the IPO added about $305.4 million net; management says the total funds operations into 2030 on a plan that includes two Phase 2 studies of ATTO-1310 and one of ATTO-2306; there is no debt, no ATM and no shelf. The quarterly loss was $20.7 million and will rise. The register is concentrated in Frazier, venBio, Alamar, Goldman Sachs, Deep Track, Redmile and Sanofi, roughly 47% between them on a Merlintrader calculation, with lock-ups to January 31, 2027, and the retail audience is nineteen watchers on Stocktwits.

The dates that structure the next year are the fourth-quarter data release, the first patient in the cholestatic pruritus study, the third quarter Form 10-Q with the money on it, the January 31 lock-up expiry, and three trial starts in the first half of 2027. The last filing by the company is the Form 10-Q of September 2, 2026.

Related Research On Merlintrader

• Top Ten Biotech Stocks Right Now — the Merlintrader biotech ranking.
• Biotech Stocks Hub 2026 — the sector index with every company hub.
• Arcutis Biotherapeutics $ARQT Stock Hub — a commercial dermatology company in atopic dermatitis and psoriasis.
• Vera Therapeutics $VERA Stock Hub — another immunology biologic on its way through the clinic.
• Weekly Market Pulse — the weekly event calendar and market map.
• Free Catalyst Calendar — every dated catalyst in one place.